Cardiogenic Shock

This page includes content on technologies to treat cardiogenic shock, including percutaneous ventricular assist devices (pVAD), intra-aortic balloon pumps (IABP) and extracorporeal membrane oxygenation (ECMO). This condition occurs when the heart can no longer pump enough oxygenated blood to the body. The most common cause of cardiogenic shock is damage to the heart from a severe heart attack. The standard of care for this condition for more than 20 years has a 50 percent survival rate, but improvements have recently been seen in studies using early pVAD intervention prior to percutaneous coronary intervention (PCI). For more information, visit the National Institute of Health (NIH) cardiogenic shock information page

the Impella pVAD improves survival, mortality in AMI heart attack with cardiogenic shock

Early use of the Impella percutaneous ventricular assist device prior to angioplasty may significantly improve survival for patients in cardiogenic shock.

Feature | Hemodynamic Support Devices | April 28, 2017 | Dave Fornell

Recent clinical study data presented at the American College of Cardiology (ACC) 2017 meeting show new treatment...

STEMI, cardiac arrest, cardiogenic shock, ACC.17 study, Minneapolis Heart Institute Foundation, MHIF
News | Cath Lab | April 03, 2017

April 3, 2017 — The influence of cardiac arrest and cardiogenic shock on outcomes of patients with...

Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study
News | Ventricular Assist Devices (VAD) | April 03, 2017

April 3, 2017 — Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic...

Videos | Hemodynamic Support Devices | March 21, 2017

This video, provided by Abiomed, demonstrates the Impella percutaneous ventricular assist devices (pVAD). It offers...

Metro Detroit cardiologists, increased heart attack survival rate, Impella heart pump, Detroit Cardiogenic Shock Initiative
News | Ventricular Assist Devices (VAD) | March 09, 2017

March 9, 2017 — Metro Detroit cardiologists from five health systems have joined together to increase residents’...

Abiomed, Impella, FDA approval, cardiogenic shock
Technology | Ventricular Assist Devices (VAD) | April 11, 2016

April 11, 2016 — Abiomed Inc. announced that it has received U.S. Food and Drug Administration (FDA) pre-market...

Maquet, extracorporeal life support, ECLS, cardiogenic shock, bridge-to-life, PLS system

PLS system image courtesy of Maquet

News | ECMO Systems | September 08, 2015

September 8, 2015 — In a new study reported in The Journal of Thoracic and Cardiovascular Surgery, researchers found...

The Abiomed Impella heart pump

The Impella percutaneous left ventricular assist devices (pLVAD) is an emerging option for partial or total circulatory support. In several randomized, controlled trials, pLVAD therapy demonstrated a better hemodynamic profile compared to IABP, although this did not translate into improved 30-day survival with use of pLVAD therapy.

Feature | September 11, 2012

September 11, 2012 — Primary results from an ongoing trial by Maquet Cardiovascular using...

Intra-aortic balloon pump (IABP) might help Therapy Aids Cardiogenic Shock Patients
News | Cardiogenic Shock | September 10, 2012

September 10, 2012 — Maquet Cardiovascular LLC announced 30-day results from the large, randomized, multicenter...

News | February 12, 2009

February 12, 2009 - Researchers in The Netherlands say the standard of care of using intra-aortic balloon...

Overlay Init